How Economic Pressure and Access Constraints Are Reshaping Pharma's Go-to-Market Model

Pharmaceutical commercialization is undergoing a major structural shift. For decades, large pharma companies relied on expansive field sales teams, in-house marketing organizations, and internally managed patient support infrastructure to drive growth. That model is becoming increasingly difficult to sustain as IRA pricing pressure, patent expirations, PBM dynamics, rising development costs, and declining physician access compress the economics of bringing drugs to market. In response, manufacturers are moving toward more modular, technology-enabled commercial models built around software, outsourced infrastructure, and measurable ROI.

This transition is creating a new generation of healthcare infrastructure companies positioned across the commercial stack, including HCP engagement, patient access, reimbursement workflows, adherence support, and digital distribution. The strongest businesses are not simply point solutions; they are deeply embedded platforms that improve workflow efficiency, generate proprietary data, and demonstrate clear commercial impact for manufacturers. Much like CROs transformed clinical development, these companies are becoming foundational infrastructure for how therapies are commercialized in a more constrained and data-driven market.

We believe this represents an attractive long-term investment theme within healthcare technology and services. As pharma companies increasingly prioritize flexible, measurable, and lower fixed-cost commercialization strategies, spend is shifting toward platforms that can improve access, targeting, patient conversion, and adherence outcomes. The result is a growing opportunity for technology-enabled infrastructure providers that sit at critical points within the modern pharma go-to-market ecosystem.

Thanks to Noor Russell for authoring this report.

‍